Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rxo (RXO) EBIT (2021 - 2025)

Rxo's EBIT history spans 5 years, with the latest figure at -$42.0 million for Q4 2025.

  • For Q4 2025, EBIT fell 75.0% year-over-year to -$42.0 million; the TTM value through Dec 2025 reached -$79.0 million, down 41.07%, while the annual FY2025 figure was -$79.0 million, 41.07% down from the prior year.
  • EBIT reached -$42.0 million in Q4 2025 per RXO's latest filing, down from -$7.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $58.0 million in Q2 2022 to a low of -$42.0 million in Q4 2025.
  • Average EBIT over 5 years is $7.5 million, with a median of $5.5 million recorded in 2023.
  • Peak YoY movement for EBIT: surged 1500.0% in 2023, then tumbled 433.33% in 2024.
  • A 5-year view of EBIT shows it stood at $55.0 million in 2021, then tumbled by 101.82% to -$1.0 million in 2022, then soared by 1500.0% to $14.0 million in 2023, then plummeted by 271.43% to -$24.0 million in 2024, then crashed by 75.0% to -$42.0 million in 2025.
  • Per Business Quant, the three most recent readings for RXO's EBIT are -$42.0 million (Q4 2025), -$7.0 million (Q3 2025), and -$30.0 million (Q1 2025).